D
espite the use of combination drug therapies, many patients still have uncontrolled hypertension. Resistant hypertension is defi ned as a blood pressure that remains above goal in spite of compliance on ≥3 antihypertensive medications of diff erent classes, one of which must be a diuretic. Renal denervation therapy attempts to address this diffi cult-to-treat population by blocking the sympathetic nerve activity to the kidneys.
Treatment of systemic hypertension with sympathectomy was initiated in the 1930s. In 1953, Smithwick and Th ompson described 1266 cases of sympathectomies performed for treatment of patients with systemic hypertension. Th ey found that there was a signifi cant mortality benefi t in the treated patients, but at a cost of a signifi cant increase in morbidity, mainly due to postural hypotension, gastrointestinal disturbances, and impotence (1). Dr. Th ompson went on to have a long and distinguished career. He practiced vascular surgery at Baylor for over 30 years, during which time he was the chairman of the Department of Surgery from 1982 to 1986. Th e Symplicity renal denervation system (Figure 1 ) is a novel treatment utilizing a minimally invasive catheter-based procedure that uses radiofrequency to ablate the sympathetic nerves lying in the renal artery. It is believed that blocking the sympathetic nervous system will lead to a reversal of fl uid and salt retention and reduce the inappropriate release of renin that is contributing to uncontrolled hypertension. Blocking the renal sympathetic nerves has also been shown to have benefi cial effects on organs damaged by chronic sympathetic overactivity, including the blood vessels, kidneys, and heart (2) .
Th e nonsurgical procedure is performed endovascularly with access through the femoral artery. Prior to denervation, a renal artery arteriogram is performed to rule out any hemodynamically signifi cant renal artery stenosis. Th e renal nerves are arborized around the renal arteries and lie within the adventitial layer of the vessel (Figure 2) . Th e Symplicity renal denervation system is placed into each renal artery, and radiofrequency ablation (5-8 watts) is performed with four to six 120-second treatments starting distally and moving proximally, with spacing of 5 mm between treatment sites.
Th e Symplicity HTN-1 Trial was a multicenter nonrandomized open-label proof-of-concept study that enrolled 153 patients with medically resistant hypertension. Patients received catheter-based renal denervation plus baseline antihypertensive medications and were followed for 36 months. At 6 months, the average drop in blood pressure in the patients was 22 mm Hg systolic and 10 mm Hg diastolic. Th ese results at 36-month follow-up showed a 33 mm Hg systolic and 19 mm Hg diastolic blood pressure reduction (Figure 3) . Th ere were no reported events of vascular injury or change in renal function (3). Th ese data led to the Symplicity HTN-2 Trial, which was a multicenter international randomized controlled study comparing renal denervation plus baseline antihypertensive medications versus baseline medications alone. After 6 months, the treatment arm had a mean reduction of 33 mm Hg in the systolic blood pressure and 12 mm Hg in the diastolic blood pressure (Figure 4) . Th e control arm did not have any change in blood pressure. Th ere were no major procedure or devicerelated events (4).
Renal denervation for resistant hypertension
Th ese two trials are the basis of the Symplicity HTN-3 Trial, which is a single-blinded, randomized controlled trial designed to evaluate the safety and eff ectiveness of the Symplicity renal denervation system in patients with resistant hypertension. Th is trial plans to enroll 530 patients who will be randomized to receive either renal denervation plus antihypertensive medications or a sham procedure and antihypertensive medications. The primary endpoints will be change in blood pressure from baseline at 6 months and the incidence of adverse events at 1 month following randomization. Th ere are three inclusion criteria: 1) having an average systolic blood pressure ≥160 mm Hg; 2) being on three antihypertensive medications, one of which is a diuretic; and 3) being 18 to 80 years old. Th e exclusion criteria include 1) hemodynamically signifi cant renal artery stenosis; 2) glomerular fi ltration rate <45 mL/min/1.73 m 2 ; 3) type I diabetes mellitus; 4) symptomatic orthostatic hypotension; 5) stenotic valvular heart disease; 6) acute coronary syndrome or cerebrovascular accident in the past 6 months; 7) planned cardiovascular intervention in the next 6 months; 8) primary pulmonary hypertension; 9) coarctation of the aorta, thyroid disorders, or Cushing's disease; and 9) alcohol or drug abuse. We at Baylor University Medical Center are currently enrolling patients for the Symplicity HTN-3 Trial.
